Abstract 37: ASPECTS and Stratified Outcomes After Endovascular Therapy in the Trevo Retriever Registry: Benefit in Low ASPECTS
Background: Most endovascular stroke therapy studies and subsequent guidelines restrict intervention based on ASPECTS. A wide range of ASPECTS scores may be encountered in practice and individual patient benefit may be realized even at low ASPECTS. We examined large-scale data on outcomes after endovascular therapy, stratified by baseline ASPECTS in the Trevo Retriever Registry.
Methods: The independent Imaging Core Lab of the Trevo Retriever Registry prospectively determines ASPECTS on baseline imaging acquired immediately prior to endovascular thrombectomy. ASPECTS scores and regional involvement were analyzed with respect to site of arterial occlusion, effect of time from symptom onset, co-morbidities and clinical outcomes, based on ASPECTS strata.
Results: Baseline ASPECTS data was reviewed by the Imaging Core Lab in 426 subjects with anterior circulation stroke enrolled in the Trevo Retriever Registry, as of July 2016. Mean age was 68.8 ± 13.7 yrs, with 20.9% > 80 years old. Baseline NIHSS was median 15.0 (10.0, 19.0). Onset to CT was median 3.8 (1.5, 9.0) hrs, with median ASPECTS of 8.0 (7.0, 9.0), ranging from 3-10. Baseline ASPECTS 0-7 occurred in 118/426 (27.7%) subjects, including 39.0% of ICA, 27.1% M1 and 16.9% M2/3 arterial occlusions at angiography. Baseline clinical variables predicting ASPECTS included age and NIHSS, whereas the ASPECTS score was mildly associated with final TICI2C reperfusion (r=0.24, p<0.001). Subsequent symptomatic ICH was 1.7% with baseline ASPECTS 0-7 versus 2.0% with ASPECTS 8-10. The distribution of mRS at 90 days based on individual ASPECTS strata from 10 to 3 revealed a trend to worse outcomes with lower ASPECTS, yet good outcomes (mRS 0-2) were 60.7% (ASPECTS 10), 55.3% (9), 60.2% (8), 54.9% (7), 55.1% (3-6).
Conclusions: Discrete ASPECTS strata may influence outcomes of endovascular therapy conducted in routine practice around the world, yet individuals with low ASPECTS may still achieve reasonable outcomes.
Author Disclosures: D.S. Liebeskind: Research Grant; Significant; NIH-NINDS. Consultant/Advisory Board; Significant; Medtronic, Stryker. G.W. Woolf: None. B. Xiang: Consultant/Advisory Board; Significant; Stryker. R. Shields: Employment; Significant; Stryker. E. Veznedaroglu: Other Research Support; Significant; this registry supported by stryker. J. English: Ownership Interest; Significant; Route 92 Medical. Consultant/Advisory Board; Modest; Silk Road Medical. Consultant/Advisory Board; Significant; Stryker, Medtronic. B.W. Baxter: Other Research Support; Significant; this registry supported by stryker. R.F. Budzik: Other Research Support; Significant; this registry supported by stryker. B.M. Bartolini: Other Research Support; Significant; this registry supported by stryker. Consultant/Advisory Board; Modest; Stryker. A. Krajina: Other Research Support; Significant; this registry supported by stryker. A. Sarraj: Research Grant; Significant; Stryker. Consultant/Advisory Board; Modest; Stryker. A. Narata: None. T. Miller: None. T. Grobelny: None. R. Gupta: None. A. Jadhav: None. R.G. Nogueira: Consultant/Advisory Board; Modest; Stryker Neurovacular (Trevo-2 Trial PI, DAWN Trial PI), Covidien (SWIFT and SWIFT-PRIME Steering Committee, STAR Trial Core Lab), and Penumbra (3-D Separator Trial Executive Committee)..
- © 2017 by American Heart Association, Inc.